Overall, our results for the first time demonstrate that pan-EGFR inhibitors (canertinib and afatinib) treatment can modulate EGFR family members and their downstream signaling along with MUC4 mucin inhibition, thereby significantly contributing towards inhibiting pancreatic cancer cell survival and metastasis (Fig. 7). This evidence concerns the gene MUC4 and familial pancreatic carcinoma.